JP2009539988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539988A5 JP2009539988A5 JP2009515453A JP2009515453A JP2009539988A5 JP 2009539988 A5 JP2009539988 A5 JP 2009539988A5 JP 2009515453 A JP2009515453 A JP 2009515453A JP 2009515453 A JP2009515453 A JP 2009515453A JP 2009539988 A5 JP2009539988 A5 JP 2009539988A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- compound according
- independently
- compound
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 403
- 229910052739 hydrogen Inorganic materials 0.000 claims description 132
- 239000001257 hydrogen Substances 0.000 claims description 132
- 229910052757 nitrogen Inorganic materials 0.000 claims description 129
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 105
- 208000002193 Pain Diseases 0.000 claims description 86
- 125000005842 heteroatom Chemical group 0.000 claims description 74
- 229910052717 sulfur Inorganic materials 0.000 claims description 74
- 229910052760 oxygen Chemical group 0.000 claims description 72
- 125000001931 aliphatic group Chemical group 0.000 claims description 64
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 62
- -1 4-substituted piperidine ring Chemical group 0.000 claims description 58
- 229920006395 saturated elastomer Polymers 0.000 claims description 58
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 53
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 52
- 239000001301 oxygen Chemical group 0.000 claims description 52
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 50
- 239000011593 sulfur Chemical group 0.000 claims description 50
- 125000002950 monocyclic group Chemical group 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 47
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 150000002367 halogens Chemical class 0.000 claims description 37
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 34
- 150000002431 hydrogen Chemical class 0.000 claims description 34
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 33
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 25
- 125000005843 halogen group Chemical group 0.000 claims description 23
- 208000004296 neuralgia Diseases 0.000 claims description 23
- 230000001154 acute effect Effects 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 21
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- 208000008035 Back Pain Diseases 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000002619 bicyclic group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000004434 sulfur atom Chemical group 0.000 claims description 14
- 208000005298 acute pain Diseases 0.000 claims description 13
- 125000002723 alicyclic group Chemical group 0.000 claims description 13
- 125000001118 alkylidene group Chemical group 0.000 claims description 13
- 230000001684 chronic effect Effects 0.000 claims description 13
- 230000002981 neuropathic effect Effects 0.000 claims description 13
- 208000021722 neuropathic pain Diseases 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 12
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims description 12
- 206010019233 Headaches Diseases 0.000 claims description 11
- 208000004404 Intractable Pain Diseases 0.000 claims description 11
- 206010028836 Neck pain Diseases 0.000 claims description 11
- 208000004550 Postoperative Pain Diseases 0.000 claims description 11
- 125000004429 atom Chemical group 0.000 claims description 11
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 206010015037 epilepsy Diseases 0.000 claims description 10
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 10
- 206010058019 Cancer Pain Diseases 0.000 claims description 9
- 208000000094 Chronic Pain Diseases 0.000 claims description 9
- 206010065390 Inflammatory pain Diseases 0.000 claims description 9
- 208000008765 Sciatica Diseases 0.000 claims description 9
- 231100000869 headache Toxicity 0.000 claims description 9
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 210000005036 nerve Anatomy 0.000 claims description 8
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 208000004998 Abdominal Pain Diseases 0.000 claims description 7
- 208000006561 Cluster Headache Diseases 0.000 claims description 7
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 7
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 7
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 7
- 206010027599 migraine Diseases 0.000 claims description 7
- 201000008482 osteoarthritis Diseases 0.000 claims description 7
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 7
- 208000009935 visceral pain Diseases 0.000 claims description 7
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 claims description 6
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 claims description 6
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 206010003591 Ataxia Diseases 0.000 claims description 5
- 208000000003 Breakthrough pain Diseases 0.000 claims description 5
- 206010021639 Incontinence Diseases 0.000 claims description 5
- 208000016285 Movement disease Diseases 0.000 claims description 5
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 206010003119 arrhythmia Diseases 0.000 claims description 5
- 230000006793 arrhythmia Effects 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 208000015706 neuroendocrine disease Diseases 0.000 claims description 5
- 208000020016 psychiatric disease Diseases 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 208000007914 Labor Pain Diseases 0.000 claims description 4
- 208000035945 Labour pain Diseases 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- 206010049816 Muscle tightness Diseases 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims description 4
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003725 azepanyl group Chemical group 0.000 claims description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 150000004885 piperazines Chemical group 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims description 2
- 206010064012 Central pain syndrome Diseases 0.000 claims description 2
- 206010008479 Chest Pain Diseases 0.000 claims description 2
- 208000002881 Colic Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 206010016059 Facial pain Diseases 0.000 claims description 2
- 206010019909 Hernia Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- 206010024229 Leprosy Diseases 0.000 claims description 2
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 206010037779 Radiculopathy Diseases 0.000 claims description 2
- 206010040037 Sensory neuropathy hereditary Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 206010043269 Tension headache Diseases 0.000 claims description 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000010304 firing Methods 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims description 2
- 201000006847 hereditary sensory neuropathy Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000003243 intestinal obstruction Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 208000001297 phlebitis Diseases 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000005198 spinal stenosis Diseases 0.000 claims description 2
- 230000007863 steatosis Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 208000026533 urinary bladder disease Diseases 0.000 claims description 2
- 208000014001 urinary system disease Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 206010059604 Radicular pain Diseases 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- PGAZQSBUJDVGIX-UHFFFAOYSA-N thiazepane Chemical group C1CCNSCC1 PGAZQSBUJDVGIX-UHFFFAOYSA-N 0.000 claims 1
- 0 *C(*)(*)C(N(*)CC1C(C2)C2N(*)C2C1C2)=O Chemical compound *C(*)(*)C(N(*)CC1C(C2)C2N(*)C2C1C2)=O 0.000 description 6
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- PAYRCEXHWORSDD-UHFFFAOYSA-N C=NNN1CCCC1 Chemical compound C=NNN1CCCC1 PAYRCEXHWORSDD-UHFFFAOYSA-N 0.000 description 1
- YQOPNAOQGQSUHF-UHFFFAOYSA-N CC(C)N1CCCC1 Chemical compound CC(C)N1CCCC1 YQOPNAOQGQSUHF-UHFFFAOYSA-N 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81276506P | 2006-06-12 | 2006-06-12 | |
| PCT/US2007/013776 WO2007146284A2 (en) | 2006-06-12 | 2007-06-12 | Thienopyrimidines useful as modulators of ion channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009539988A JP2009539988A (ja) | 2009-11-19 |
| JP2009539988A5 true JP2009539988A5 (https=) | 2010-07-15 |
Family
ID=38828498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515453A Pending JP2009539988A (ja) | 2006-06-12 | 2007-06-12 | イオンチャネルの調節因子として有用なチエノピリミジン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8883781B2 (https=) |
| EP (1) | EP2043654A2 (https=) |
| JP (1) | JP2009539988A (https=) |
| KR (1) | KR20090021218A (https=) |
| CN (1) | CN101500575A (https=) |
| AU (1) | AU2007258313A1 (https=) |
| CA (1) | CA2654842A1 (https=) |
| IL (1) | IL195861A0 (https=) |
| MX (1) | MX2008015908A (https=) |
| NO (1) | NO20090157L (https=) |
| RU (1) | RU2009100159A (https=) |
| WO (1) | WO2007146284A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005003632A1 (de) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Katheter für die transvaskuläre Implantation von Herzklappenprothesen |
| US8876894B2 (en) | 2006-09-19 | 2014-11-04 | Medtronic Ventor Technologies Ltd. | Leaflet-sensitive valve fixation member |
| US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
| WO2011104269A1 (en) | 2008-02-26 | 2011-09-01 | Jenavalve Technology Inc. | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
| US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
| US8952034B2 (en) * | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| US10856978B2 (en) | 2010-05-20 | 2020-12-08 | Jenavalve Technology, Inc. | Catheter system |
| CN103002833B (zh) | 2010-05-25 | 2016-05-11 | 耶拿阀门科技公司 | 人工心脏瓣及包括人工心脏瓣和支架的经导管输送的内假体 |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| TW201219401A (en) * | 2010-09-14 | 2012-05-16 | Lexicon Pharmaceuticals Inc | Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use |
| GB201105659D0 (en) | 2011-04-01 | 2011-05-18 | Xention Ltd | Compounds |
| CA2834164A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused benzoxazinones as ion channel modulators |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| AR090037A1 (es) * | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| WO2015028209A1 (en) | 2013-08-30 | 2015-03-05 | Jenavalve Technology Gmbh | Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame |
| WO2016150806A1 (en) | 2015-03-20 | 2016-09-29 | Jenavalve Technology, Inc. | Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath |
| CN107530168B (zh) | 2015-05-01 | 2020-06-09 | 耶拿阀门科技股份有限公司 | 在心脏瓣膜替换中具有降低的起搏器比例的装置和方法 |
| JP7114076B2 (ja) | 2015-12-22 | 2022-08-08 | シャイ・セラピューティクス・エルエルシー | がん及び炎症性疾患の処置のための化合物 |
| CN109475419B (zh) | 2016-05-13 | 2021-11-09 | 耶拿阀门科技股份有限公司 | 用于通过引导鞘和装载系统来递送心脏瓣膜假体的心脏瓣膜假体递送系统和方法 |
| US10961253B2 (en) * | 2016-11-07 | 2021-03-30 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| WO2018085803A1 (en) * | 2016-11-07 | 2018-05-11 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| CN110392557A (zh) | 2017-01-27 | 2019-10-29 | 耶拿阀门科技股份有限公司 | 心脏瓣膜模拟 |
| JP7514005B2 (ja) | 2017-06-21 | 2024-07-10 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物 |
| JP7407461B2 (ja) | 2018-12-19 | 2024-01-04 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物 |
| CN120152682A (zh) | 2022-11-09 | 2025-06-13 | 耶拿阀门科技公司 | 用于顺序地部署可扩张植入物的导管系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2133815A1 (en) * | 1993-10-12 | 1995-04-13 | Jeffrey Alan Dodge | Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| EP1638955A2 (en) * | 2003-07-02 | 2006-03-29 | Vertex Pharmaceuticals Incorporated | Pyrimidines useful as modulators of voltage-gated ion channels |
| ZA200601859B (en) * | 2003-08-05 | 2008-03-26 | Vertex Pharma | Condensed pyrimidine compounds as inhibitors of voltagegated ion channels |
| BRPI0514893A (pt) * | 2004-09-02 | 2007-11-27 | Vertex Pharma | quinazolinas úteis como moduladores de canais de ìon |
| EP1806347A4 (en) * | 2004-10-08 | 2009-07-01 | Astellas Pharma Inc | PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING |
| PE20060608A1 (es) * | 2004-10-13 | 2006-08-22 | Wyeth Corp | Analogos de 17-hidroxiwortmanina como inhibidores de pi3k |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
-
2007
- 2007-06-12 EP EP07796018A patent/EP2043654A2/en not_active Withdrawn
- 2007-06-12 MX MX2008015908A patent/MX2008015908A/es unknown
- 2007-06-12 KR KR1020097000621A patent/KR20090021218A/ko not_active Withdrawn
- 2007-06-12 JP JP2009515453A patent/JP2009539988A/ja active Pending
- 2007-06-12 WO PCT/US2007/013776 patent/WO2007146284A2/en not_active Ceased
- 2007-06-12 AU AU2007258313A patent/AU2007258313A1/en not_active Abandoned
- 2007-06-12 CA CA002654842A patent/CA2654842A1/en not_active Abandoned
- 2007-06-12 RU RU2009100159/15A patent/RU2009100159A/ru not_active Application Discontinuation
- 2007-06-12 US US11/811,909 patent/US8883781B2/en active Active
- 2007-06-12 CN CNA2007800297622A patent/CN101500575A/zh active Pending
-
2008
- 2008-12-11 IL IL195861A patent/IL195861A0/en unknown
-
2009
- 2009-01-12 NO NO20090157A patent/NO20090157L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539988A5 (https=) | ||
| RU2009100159A (ru) | Тиенопирамидины, полезные в качестве модуляторов ионных каналов | |
| DE69122084T2 (de) | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel | |
| JP6675334B2 (ja) | 脊髄性筋萎縮症を処置するためのイミダゾ［１，２−ａ］ピラジン−１−イルベンズアミド化合物 | |
| RU2007116858A (ru) | Тиазолилдигидроиндазолы | |
| EP3684772B1 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| EP0600949B1 (de) | Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel | |
| EP1230230B1 (de) | Indeno-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel | |
| EP1259498B1 (de) | 8,8a-dihydro-indeno [1,2-d]thiazol-derivate, die in 8a-stellung substituiert sind, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel z.b. als anorektika | |
| DE19912638A1 (de) | Naphthylcarbonsäureamid-substituierte Sulfonamide | |
| JP2024174864A (ja) | ニトロキソリンプロドラッグ及びその使用 | |
| JP2008511670A5 (https=) | ||
| JP2010504956A (ja) | 新規なジチオロピロロンおよびそれらの治療的応用 | |
| JP2008540443A5 (https=) | ||
| EP1142885B1 (en) | 2-(n-cyanoimino)thiazolidin-4-one derivatives | |
| JP2008540438A5 (https=) | ||
| CN109937203B (zh) | 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物 | |
| CN1258277A (zh) | 细胞增生抑制剂氰基胍 | |
| JP2008540665A5 (https=) | ||
| JP2008542377A5 (https=) | ||
| PL207487B1 (pl) | Pochodna aminobenzofenonu o wzorze I, jej zastosowanie i kompozycja zawierająca ten związek | |
| RU2011136855A (ru) | Производные бензотиазолов и бензимидазолов, содержащие 6-nh-замещенные триазолопиридазинсульфанил в положении 6: получение, применение в качестве лекарственных средств и применение в качестве ингибиторов мет | |
| US11472815B2 (en) | 1,4-diphenyl-1H-imidazole and 2,4-diphenylthiazole derivatives and preparation method therefor and use thereof | |
| CN109422751B (zh) | 一类具有降解酪氨酸蛋白激酶jak3活性的化合物 | |
| ES2974946T3 (es) | Compuestos (7H-pirrolo[2,3-d]pirimidin-4-il)amino sustituidos útiles como inhibidores de JAK1 |